Cholangiocarcinoma-on-a-chip for personalised medicine
2023
Humanitas University, Milan, Italy
Cholangiocarcinoma (CCA) is a primary liver tumour characterised by a poor prognosis and limited therapeutic options. Here, an innovative patient-specific cholangiocarcinoma (CCA)-on-chip platform was successfully developed, integrating the major components of the tumour microenvironment (tumour cells, cancer-associated fibroblasts, endothelial cells, and immune infiltrate) and faithfully mimicking the CCA niche. Primary CCA cells from 6 patients were used, and patient-specific reactions were measured in the chips. A drug trial showed the ability of the device to recapitulate different drug responses based on patient characteristics. This CCA-on-chip represents a powerful tool for unravelling disease-associated cellular mechanisms in CCA and provides an efficient tool for personalised drug testing.
Cholangiocarcinoma-on-a-chip: A human 3D platform for personalised medicine
Ana Lleo
Added on: 04-02-2024
[1] https://www.jhep-reports.eu/article/S2589-5559(23)00241-0/fulltext[2] https://www.drugtargetreview.com/news/128044/advancing-personalised-medicine-with-a-cholangiocarcinoma-model/
